Masimo Corp. today announced preliminary financial results for the fourth quarter and full year.
The Irvine-based medical device maker expects fourth quarter revenue to increase 12% to $411 million and full year revenue to grow 9% to $1.5 billion.
“In 2025, we achieved a record level of incremental contract value from new customers and expanded hospital agreements with our existing customers, which positions us well for sustained performance in the year ahead,” Chief Executive Katie Szyman said in a statement.
Despite beating analysts’ expectations, shares fell 4% to $133.35 and a $7.2 billion market cap. Masimo on Jan. 5 hit a 52-week low of $125.94.
The company will release complete financial results on Feb. 26 after the market closes.
